India has taken a major step in the fight against dengue. The Drug Controller General of India (DCGI) has granted marketing authorisation to Qdenga, developed by Japan’s Takeda, making it the first vaccine ever approved for the prevention of dengue in India. Here’s what makes this approval significant, and what it means for you.
What is Qdenga, and who can take it?
Qdenga is a live, attenuated tetravalent vaccine built on a dengue virus type-2 backbone, into which genes from the other three dengue serotypes have been inserted — giving it balanced protection against all four dengue strains (DENV-1, DENV-2, DENV-3, and DENV-4). It has been approved for people aged between 4 and 60 years, and is given as a 0.5 ml injection under the skin, in two doses three months apart.
The standout feature: no pre-vaccination testing needed
This is what sets Qdenga apart from earlier dengue vaccines. It can be administered irrespective of a person’s prior dengue infection status, eliminating the need for pre-vaccination screening. This matters a lot in practice. Sanofi’s Dengvaxia, which isn’t approved in India, is recommended only for people who’ve already had a dengue infection, because in people without prior exposure it was linked to a higher risk of severe dengue. That safety complication made large-scale rollout difficult. Qdenga sidesteps this problem entirely, which is what makes it a more practical option for mass immunisation.
How well does it actually work?
The approval rests on Takeda’s global clinical programme spanning more than 28,000 participants across 19 Phase I, II and III trials, plus a Phase III study conducted in India assessing safety and immune response in people aged 4–60. The headline numbers come from the pivotal international trial: the Phase III TIDES trial, involving over 20,000 participants across eight dengue-endemic countries, showed 80.2% efficacy against confirmed dengue infection one year after the second dose, 90.4% efficacy against dengue-related hospitalisation at 18 months, and 84.1% efficacy in further follow-up analysis.
source: Business StandardBusiness Standard
Why this approval matters for India specifically
India carries an enormous share of the global dengue burden. India accounts for nearly one-third of the world’s dengue cases, and reported cases in the country have grown more than 11-fold over the past two decades. Until now, India’s dengue response has relied almost entirely on mosquito control, surveillance, and public awareness, since there is no specific antiviral treatment for dengue — only supportive care. Qdenga gives the country its first vaccine-based prevention strategy to add alongside these existing efforts.
Qdenga also already has a track record elsewhere: it’s been approved in more than 40 countries and holds WHO prequalification, meaning it meets international benchmarks for quality, safety, and effectiveness — and is eligible for procurement by global agencies like UNICEF and PAHO.